STAT+: Amgen's Repatha linked to fewer heart attacks

According to STAT+, Amgen's Repatha is linked to fewer heart attacks, though the available context provides no further details on this finding. The same briefing text separately notes that Novartis has disclosed seven previously unreported cases of tumors in children who received its Zolgensma gene therapy.

Headlines are indexed or machine translated, not independent verification of scientific results. Medical news is not clinical advice. Distinguish interstellar concepts from demonstrated space technology using the original source.